Home Mercks BRIDION (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery
 

Keywords :   


Mercks BRIDION (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery

2015-12-17 23:52:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BRIDION (sugammadex) Injection 100 mg/mL (equivalent to 108.8 mg/mL sugammadex sodium) for the reversal of neuromuscular blockade (NMB) induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558Doris Li, 908-740-1903orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 read more

Tags: approval adults surgery induced

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
14.1115kg 50mm
14.11ONE PIECE BOX
14.11DAIWA OCEAN STAR 500
14.11fender jhon mayer blackone
14.11 Angel Touch Plus vol.3
14.11Strymon BigSky
14.11
14.11 TOUR B X 2
More »